PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2

The HVEM-BTLA Axis Restrains T Cell Help to Germinal Center B Cells and Functions as a Cell-Extrinsic Suppressor in Lymphomagenesis

(2019) Michelle A. Mintz et al.   IMMUNITY

Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy

(2019) Javier Celis-Gutierrez et al.   Cell Reports

Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells

(2018) Yunlong Zhao et al.   Cell Reports

Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo

(2018) Giorgia Rota et al.   Cell Reports

FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells

(2018) Xiangbo Meng et al.   NATURE

CD4 + T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness

(2017) Tomasz Ahrends et al.   IMMUNITY

Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor

(2017) Michael Peled et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

(2017) Enfu Hui et al.   SCIENCE

Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent

(2017) Alice O. Kamphorst et al.   SCIENCE

Biophysical assay for tethered signaling reactions reveals tether-controlled activity for the phosphatase SHP-1

(2017) Jesse Goyette et al.   Science Advances

Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family

(2016) Frank A. Schildberg et al.   IMMUNITY

Using the Ubiquitin-modified Proteome to Monitor Distinct and Spatially Restricted Protein Homeostasis Dysfunction

(2016) Joshua M. Gendron et al.   MOLECULAR & CELLULAR PROTEOMICS

BTLA identifies dysfunctional PD-1-expressing CD4+ T cells in human hepatocellular carcinoma

(2016) Qiyi Zhao et al.   OncoImmunology

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

(2015) Naiyer A Rizvi et al.   LANCET ONCOLOGY

The cytotoxic T cell proteome and its shaping by the kinase mTOR

(2015) Jens L Hukelmann et al.   NATURE IMMUNOLOGY

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Overcoming T cell exhaustion in infection and cancer

(2015) Kristen E. Pauken et al.   TRENDS IN IMMUNOLOGY

Inhibitory Receptors Beyond T Cell Exhaustion

(2015) Silvia A. Fuertes Marraco et al.   Frontiers in Immunology

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

In vitro membrane reconstitution of the T-cell receptor proximal signaling network

(2014) Enfu Hui et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity

(2013) Christine Pasero et al.   IMMUNOLOGY LETTERS

Structure and Interactions of the Human Programmed Cell Death 1 Receptor

(2013) Xiaoxiao Cheng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PD-1 Increases PTEN Phosphatase Activity While Decreasing PTEN Protein Stability by Inhibiting Casein Kinase 2

(2013) Nikolaos Patsoukis et al.   MOLECULAR AND CELLULAR BIOLOGY

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2

(2012) Tadashi Yokosuka et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization

(2012) Lukas Baitsch et al.   PLoS One

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1

(2011) J. Fourcade et al.   CANCER RESEARCH

Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients

(2011) Lukas Baitsch et al.   JOURNAL OF CLINICAL INVESTIGATION

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

The 4G10, pY20 and p-TYR-100 antibody specificity: profiling by peptide microarrays

(2011) Michele Tinti et al.   New Biotechnology

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination

(2010) Laurent Derré et al.   JOURNAL OF CLINICAL INVESTIGATION

SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels

(2009) Ulrike Lorenz   IMMUNOLOGICAL REVIEWS

PD-1 signaling in primary T cells

(2009) James L. Riley   IMMUNOLOGICAL REVIEWS

T Cell Intrinsic Heterodimeric Complexes between HVEM and BTLA Determine Receptivity to the Surrounding Microenvironment

(2009) T. C. Cheung et al.   JOURNAL OF IMMUNOLOGY

Inactivation of SHIP1 in T-cell acute lymphoblastic leukemia due to mutation and extensive alternative splicing

(2009) Tony C.T. Lo et al.   LEUKEMIA RESEARCH

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator

(2008) Guifang Cai et al.   NATURE IMMUNOLOGY